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Summary Unique germline mutations in BRCA1 and BRCA2 account for inherited predisposition to breast and ovarian cancer in high-risk
families. In Jewish high-risk individuals of Ashkenazi (east European) descent, three predominant mutations, 185delAG and 5382insC
(BRCA1) and 6174delT(BRCA2), seem to account for a substantial portion of germline mutations, and two of these mutations (185delAG and
6174deIT) are also found at about 1% each in the general Jewish-Ashkenazi population. We identified a novel BRCA1 mutation in two
Jewish-non-Ashkenazi families with ovarian cancer: a thymidine to guanidine alteration at position 3053, resulting in substitution of tyrosine
at codon 1017 for a stop codon (Tyr1017Ter). The mutation was first detected by protein truncation test (PTT) and confirmed by sequencing
and a modified restriction digest assay. Allelotyping of mutation carriers using intragenic BRCA1 markers revealed that the haplotype was
identical in these seemingly unrelated families. No mutation carrier was found among 118 unselected Jewish individuals of Iranian origin. Our
findings suggest that this novel mutation should be incorporated into the panel of mutations analysed in high-risk families of the appropriate
ethnic background, and that the repertoire of BRCA1 mutations in Jewish high-risk families may be limited, regardless of ethnic origin.
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Germline mutations in BRCAJ and BRCA2 genes presumably
account for the genetic predisposition and increased risk for breast
and ovarian cancer in the majority of families with inherited
predisposition to these cancers (Hall et al, 1990; Easton et al,
1993; Miki et al, 1994; Wooster et al, 1995). Thus far, more than
100 germline mutations have been identified within the BRCAJ
gene (Castilla et al, 1994; Szabo and King, 1995; Langston et al,
1996), as well as several dozen in BRCA2, that, by and large, are
unique to each high-risk family. A notable exception are the
Jewish high-risk individuals, in whom three predominant muta-
tions, 185delAG and 5382insC (BRCAI) and 6174delT (BRCA2),
seem to account for a substantial proportion ofgermline mutations
(Abeliovich et al, 1997). Moreover, two of these predominant
mutations, 185delAG and 6174delT, are also found in the general
Jewish-Ashkenazi population at a surprisingly high rate of
approximately 1% each; the 5382insC mutation is found at slightly
lower rates (Streuwing et al, 1995; O'ddoux et al, 1996). Our
previous studies show that 185delAG mutation carriers can be
detected in Jewish non-Ashkenazi populations at rates approxi-
mately similar to the Ashkenazi population (Bruchim et al, manu-
script submitted). Population-based studies have defined high- and
low-risk subsets for developing breast and ovarian cancer, based
partly on ethnic origin (IARC, 1987). In Israel, Jewish women of
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Ashkenazi (east European) origin are considered at high risk for
developing breast and ovarian cancers over non-Ashkenazi
women, who are considered to be a low-risk population (Israel
Cancer Registry, 1992). Depending on the country of origin, the
Jewish population is divided into Ashkenazi and non-Ashkenazi
subsets. The latter group includes diverse countries oforigin, such
as North Africa, Iraq, Yemen, Turkey, Bulgaria and Holland. This
distinction, in turn, represents the origin of the early ancestors of
the Jewish people ofthese ethnic subgroups since thedispersion of
the Jews in the diaspora circa 70AD and since the Spanish depor-
tation in 1492 (Goodman, 1979; Motulsky, 1995).
Except for the three predominant mutations mentioned above,
no other mutations have been previously reported in Jewish high-
risk individuals from ovarian cancer-prone families. Here, we
report the first novel mutation detected in Israeli high-risk families
of non-Ashkenazi (Iranian and Afghani) origin. Additionally, we
analysed mutation carriers for haplotype-sharing with intragenic
BRCAJ markers and developed a rapid detection test for this
specific mutation. The rapid screening test was applied for
screening ofthe occurrence ofthis mutation in an unselected panel
ofJewish-Iranian men and women.
MATERIALS AND METHODS
DNA isolation and polymerase chain reaction (PCR) of
genomic DNA
Genomic DNA was prepared from anticoagulated blood samples
as described (Miller et al, 1988). For P7TT analysis, three partly
overlapping fragments covering exon 11 of the BRCAI gene were
generated by PCR using 100 ng ofgenomic DNA. PCR protocols
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and cycling profiles were performed as previously described by
Hogervorst and co-workers (Hogervorst et al, 1995). Forward
primers contain a T7 promoter sequence and a eukaryotic transla-
tion initiation sequence.
Protein truncation test (PTT)
PCR products of expected sizes were used for PTT analysis. PTT
analysis was carried out by adding 200-400 ng ofT7 PCR product
to the TnT/T7 coupled reticulocyte lysate system (Promega,
Madison, WI, USA). The synthesized protein products were sepa-
rated on a 12% SDS-polyacrylamide minigel system (Bio-Rad,
Richmond, CA, USA). Gels were dried and exposed to a radio-
graphic film for 16-40 h at - 70°C or room temperature for
autoradiography.
Sequence analysis of abnormal PUT fragments
PCR ofthe fragments suspected ofbearing a mutation were gener-
ated, using a biotinylated primer. Biotinylated DNA fragments
were immobilized onto strepavidin-coated magnetic beads (Dynal,
Oslo, Norway) and denatured to produce single-stranded
templates. These templates were sequenced on the solid phase,
using USB Sequenase version 2 kit, with [35S]dATP, as previously
described (Syvanen et al, 1989). The samples were size separated
on 6% acrylamide gel at 60 W for 2 h, and then gels were dried
and autoradiographed for 24-72 h.
Rapid screening test
Two sets of oligonucleotide primers were designed to amplify
genomic DNA for the region encompassing the mutation. Each
forward primer contained one base substitution to generate a
restriction site within the mutated or the wild-type allele, after
PCR amplification with acommon reverse primer. The first primer
sequence (A) was: 5'-AAA-CAT-GGA-CTT-TTA-CAA-AAC-
CGA-TA-3' (position 3027-3052 on the cDNA with a C to T
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Figure 1 Pedigree and haplotype in family A. Pedigree (top) and haplotype
(bottom) offamily A. Proband is patient 11-1. Haplotypes clearly show an
identical allelic pattern in mutation carriers with 17q markers (left). The
asterix denotes an affected (black circle) or an asymptomatic carrier (grey
circle)
(position 3027-3052 on the cDNA with a C to G substitution at
position 3049). The reverse primer corresponded to position
3177-3201. PCRreaction volume was 50 1l and included 30 pmol
of each primer, 0.2 units of red-hot Taq polymerase (Advanced
Biotechnologies, Leatherhead, Surrey, UK), with the AB PCR
buffer supplied by the manufacturer (1.5 mm magnesium chlo-
ride), and the other standard PCR constituents. Amplification was
achieved using PTC 60-100 (MJ Research, Watertown, MA,
USA) and the cycling profile was as follows: denaturation at 940C
for 4 min followed by 30 cycles of denaturation (94-45 s),
annealing (52-1 min) and extension (72-2 min), with a final
extension step of 5 min at 72°C. PCR products were analysed on
2% agarose gels to assess the specificity and success of the reac-
tion, and were visualized with ethidium bromide. PCR products
generated with primer A and the reverse primer were digested
with the restriction enzyme EcoRV (Boehringer Mannheim,
Mannheim, Germany), which digests only the wild-type allele but
not the mutant allele. PCR products generated with primer B and
the reverse primer were digested with the restriction enzyme BfinI
(MBI-Fermentas, Vilnius, Lithuania), which digests only the
mutant allele but not the wild-type allele. Restriction enzyme
digest products were separated on 4% Metaphore agarose (FMC,
Rockland, ME, USA) gels visualized with ethidium bromide.
Haplotype analysis
For haplotype analysis, markers intragenic to the BRCAJ
gene were used: D17S855, D17S1322 and D17S1323. PCR
amplification, gel electrophoresis and autoradiography were
performed using standard protocols, as previously described
(Berman et al, 1996).
Population study
One hundred and eighteen Jewish Persian-origin individuals (58
men and 60 women) were anonymously tested for the TyrlO17ter
germline mutation. The individuals were previously identified and
voluntarily recruited from various departments and outpatient
clinics of the Sheba Medical Center, without preselection for
history of cancers. All tested individuals were unrelated to each
other. The study was approved by the Human Subject Ethics
Committee. The Iranian ancestry of study participants was
confirmed at least three generations back.
RESULTS
Patients' clinical characteristics
In family A, ofJewish Persian origin, ovarian cancer in the index
case was diagnosed at age 40 years. The patient's mother had
ovarian cancer diagnosed at age 60 years, and a maternal aunt had
ovarian cancer diagnosed at age 20 years (Figure 1). In family B,
an apparently unrelated Jewish family from Afghanistan, age at
diagnosis ofthe index case was 42 years and the motherdeveloped
ovarian cancer at 52 years ofage. No other known affected family
members could be ascertained. These two families were analysed
as part of the oncogenetics service at the Sheba Medical Center,
which counsels and tests high-risk individuals. In a 2-year period,
91 families of non-Ashkenazi origin, ascertained as high risk for
breast and ovarian cancer were evaluated, five were of Iranian
origin and one ofAfghani origin.
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Figure 2 Sequence analysis of the mutant (left) and a normal (right). The
arrow on the left shows a heterozygote mutation (T to G substitution) at
position 3053 (arrow), not present in the wild-type sequence
Protein truncation test (PTT) and sequence analysis of
index cases
DNA samples from index cases from both families were amplified
by PCR using three primer pairs (A, B and C) that encompass
BRCAJ exon 11 in slightly overlapping fragments, as previously
described (Hogervorst et al, 1995). PCR products of the expected
size were analysed by ethidium bromide stain (data not shown)
and subjected to PTT analysis. Both index cases had a typical
pattern of atruncating mutation within fragment B: a normal-sized
protein band and atruncated, smaller size band. Direct sequencing
of these abnormal fragments using biotinylated primer revealed a
thymidine to guanidine substitution at position 3053 (Figure 2).
This is a non-sense mutation, substituting Tyrosine at codon 1017
for a stop codon (Tyr 1017ter).
Rapid screening test and sequence confirmation
For confirmation and rapid screening of the TyrlO17ter mutation,
two sets of modified PCR primers were designed for modified
restriction assay (see Materials and methods). After PCR amplifi-
cation and restriction digests, DNA from individuals shown to be
heterozygous for the mutation by PTT and sequencing was further
confirmed by digestion with EcoRV and withBfinl.
Haplotype analysis of mutation carriers with intragenic
BRCA1 markers
Using three intragenic BRCA1 microsatellite markers, the allelic
patterns of the TyrlO17ter mutation carriers was determined. All
mutation carriers from both families displayed an identical haplo-
type (Figure 1). This haplotype was distinctly different from the
common Ashkenazi haplotype in 185delAG mutation carriers and
was not detected in any of 100 alleles tested in individuals from
the general Jewish-Iranian population.
The Tyrl017ter mutation in the general Jewish-Iranian
population
The occurrence of the TyrlO17ter mutation was evaluated in a
panel of Jewish-Iranian men and women (n = 118), whose DNA
was available through previous screening of factor XI deficiency
(Shpilberg et al, 1995) and who were unselected for personal or
familial history of cancer. In the two PCR variations, none of the
DNA examined showed arestriction pattern suggestive ofthe exis-
tence of a mutant allele. We could not screen for the occurrence of
this mutation in Jews of Afghan origin as no one of this ethnic
origin was available for our study.
DISCUSSION
We detected a novel BRCAJ germline mutation in two apparently
unrelated Jewish-Israeli families ofIranian and Afghani extraction
with a history ofovarian cancer. This is the first original mutation
described in Jewish high-risk individuals, in addition to the well-
known predominant mutations in high-risk families and the
general Jewish-Ashkenazi population, i.e. 185delAG, 5382insC
(BRCAI) (Streuwing et al, 1995; Abeliovich et al, 1997) and
6174delT (BRCA2) (Odduoux et al, 1996; Abeliovich et al, 1997).
It is probable that this mutation is of pathological significance
as it results in a truncated protein. In our experience at the
Oncogenetics Unit at the Sheba Medical Center, and those ofother
oncogenetics units in Israel (Abeliovich et al, 1997), there are only
four germline mutations in BRCAJ and BRCA2 that have been
detected in Jewish high-risk individuals. We have not detected any
individual with the 188del11 mutation that was reported by
Berman and co-workers as being prevalent in women of
Ashkenazi-Jewish extraction (Berman et al, 1996). Our finding of
an identical mutation in high-risk individuals of non-Ashkenazi
origin may indicate that the prevalence of this mutation in non-
Ashkenazi at-risk individuals should be assessed, perhaps using
the rapid screening test reported herein. Ifprevalence data confirm
that this mutation is indeed common in this ethnic subgroup, then
perhaps the scope of mutation screening in high-risk families in
Israel should be expanded to include this novel mutation.
The tumourous phenotype associated with this mutation
includes ovarian cancer only, with no cases ofbreastcancer. Itis of
note that germline mutations occurring at the 5' two-thirds of the
BRCAJ gene are associated with a higher rate of ovarian cancer,
compared with the 3' third ofthe gene (Gaytheret al, 1995). In that
respect, the mutation reported herein conforms with this suggested
genotype-phenotype correlation. It remains to be seen whether
families of the same ethnic origin, in whom the phenotype
includes breast cancer, do display this mutation.
The mutation occurred in the backdrop of a common haplotype
when markers intragenic to the BRCAJ gene were used. This
finding suggests that the TyrlO17ter mutation carriers are all
descendants of an ancient founder. The possibility that germline
mutations in BRCAJ are associated with an as yet unspecified
biological advantage can not be ruled out. Support for this notion
may come from the surprisingly high prevalence of 185delAG and
6174delT mutation carriers in the Jewish-Ashkenazi population.
The mere fact that these mutations survived the selective pressure
throughout multiple generations needs to be explained and not
simply dismissed as representing founder effect. Indeed, non-
Jewish (Berman et al, 1996) and some Jewish-non-Ashkenazi
(Bruchim et al, manuscript submitted) 185delAG mutation carriers
have been found to have haplotypes distinct from Ashkenazi muta-
tion carriers. Alternatively, the selective pressure against these
mutations may not play a role, as disease manifestations occur at a
post-childbearing age.
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The number of Jewish-Iranian patients with ovarian cancer in
Israel is small; five to ten such individuals have been reported to
the Israel Cancer Registry annually during the past 10 years (Israel
Cancer Registry, 1992). The mutation was detected in one of five
Iranian families and in the only Afghan family tested. Thus,
finding an identical mutation in two families of this ethnic origin
may signify that a substantial proportion of Iranian individuals at
high risk for ovarian cancer may bear this mutation, as well as in
other Jewish patients originating from geographically proximate
areas, e.g. Iraq, India, etc.
We did not detect this germline mutation in a panel of 118 unse-
lected men and women ofJewish-Persian origin. This finding is in
contrast to the 1% rate of mutation carriers in other BRCAJ and
BRCA2 mutations in the Ashkenazi population (Streuwing et al,
1995; Odduoux et al, 1996). Several interpretations should be
considered: the sample size is insufficient to detectthis mutation in
the general population or there is a selection bias in the patients
seen at our medical centre such that there is no adequate represen-
tation ofthe Iranian subpopulation.
ACKNOWLEDGEMENTS
This work was performed in partial fulfillment ofthe requirements
for the Ph.D. degree of R Bar-Sade from the Sackler School of
Medicine at the Tel-Aviv University. We would like to thank Drs U
Seligsohn and A Zivelin for providing the Jewish-Iranian DNA
samples. We would like to thank Ms Bianna Feritz, Ms Inna
Muller and Ms Bella Ziefffor expert technical assistance.
REFERENCES
Abeliovich D, Kaduri L, Lerer I, Weinberg N, Gail A, Sagi M, Zlotogora J, Heching
N and Pertz T (1997) The founder mutations 185delAG and 5382insC in
BRCA1 and 6174delT in BRCA2 appear in 60% ofovarian cancer and 30% of
early onset breast cancer patients among Ashkenazi women. Am J Hum Genet
60: 505-514
Berman DB, Wagner-Costalas J, Schultz DC, Lynch DC, Daly M and Godwin AK
(1996) Two distinct origins of a common mutation in breast-ovarian cancer
families: a genetic study of 15 185delAG-mutation kindreds. Am JHum Genet
58: 1166-1176
Castilla LH, Couch FJ, Erdos MR, Hoskins KF, Calzone K, Garber JE, Boyd J,
Lubin MB, Deshano ML, Brody LC, Collins FS and Weber BL (1994)
Mutations in the BRCAI gene in families with early-onset breast and ovarian
cancer. Nature Genet 8: 387-398
Easton DF, Bishop DT, Ford D, Cockford GP and the Breast Cancer Linkage
Consortium (1993) Genetic linkage analysis in familial breast and ovarian
cancer. Am J Hum Genet 52: 718-722
Gayther SA, Warren W, Mazoyer S, Russel PA, Harrington PA, Chiano M, Seal S,
Hamoudi R, van Rebnsburg EJ, Dunning AM, Love R, Evans G, Easton D,
Clayton D, Stratton MR and Ponder BAJ (1995) Germline mutations ofthe
BRCA1 gene in breast and ovarian cancer families provide evidence for a
genotype phenotype correlation. Nature Genet 11: 428-433
Goodman RM (1979) A perspective ofgenetic diseases among the Jewish people. In
Genetic Diseases Among Ashkenazi Jews. Goodman RM and Moutulsky AG.
pp. 10-34 (eds), Raven Press: New York
Hall JM, Lee MK, Newman B, Morrow JE, Anderson LA, Huey B and King MC
(1990) Linkage ofearly-onset familial breast cancer to chromosome 17q21.
Science 250: 1684-1689
Hogervorst FBL, Comelis RS, Bout M, van Vliet M, Oosterwijk C, Olmer R,
Bakker B, Klijn JGM, Vasen HFA, Meijers-Heijboer H, Menko FH, Comelisse
CJ, den Dunnen JT, Devilee P and van Ommen GJB (1995) Rapid detection of
BRCAI mutations by the protein truncation test. Nature Genet 10: 208-212
IARC (1987) Cancer Incidence in Five Continents, Vol. 5. IARC: Lyon
Israel Cancer Registry (1992) Cancer in Israel: Facts and Figures 1982-1986. Israel
Cancer Registry: Jerusalem
Langston AA, Malone KE, Thompson JD and Ostrander EA (1996) BRCAI
mutations in a population-based sample ofyoung women with breast cancer.
NEnglJMed 334: 137-142
Miki Y, Swensen J, Shattuck-Eidens D, Futreal PA, Harsman K, Tavtigian S, Liu Q,
Cochran C, Bennet LM, Ding W, Bell R, Rosenthal J, Hussey C, Tran T,
McClure M, Frye C, Hattier T, Pelps R, Haugen-Strano A, Katcher H, Yakumo
K, Gholami Z, Shaffer D, Stone S, Bayer S, Wray C, Bogden R, Dayananth P,
Ward J, Tonin P, Narod S, Bristow PK, Norris FH, Helvering L, Morrison P,
Rosteck P, Lai M, Barrett JC, Lewis C, Neuhausen S, Cannon-Albright L,
Goldgar D, Wessman R, Kamb A and Skolnick MH (1994) A strong candidate
for the breast and ovarian cancer susceptibility gene BRCA1. Science 266:
66-71
Miller SA, Dykes DD and Polesky HF (1988) A simple salting out procedure for
extracting DNA from human nucleated cells. Nucleic Acids Res 16: 1215
Motulsky AG (1995) Jewish diseases and origins. Nature Genet 9: 99-101
Odduoux C, Streuwing JP, Clayton CM, Neuhausen S, Brody LC, Kaback M, Haas
B, Norton L, Borgen P, Jhanwar S, Goldgar D, Ostrer H and Offit K (1996) The
carrier frequency ofthe BRCA2 6174delT mutation among Ashkenazi Jewish
individuals is approximately 1%. Nature Genet 14: 188-190
Shpilberg 0, Peretz H, Zivelin A, Yatuv R, Chetrit A, Kulka T, Stem C, Weiss E and
Seligsohn U (1995) One ofthe two common mutations causing factor XI
deficiency in Ashkenazi Jews (Type II) is also prevalent in Iraqi Jews, who
represent the ancient gene pool ofJews. Blood85: 429-432
Streuwing JP, Abeliovitch D, Peretz T, Avishai N, Kaback MM, Collins FS and
Brody LC (1995) The carrier frequency ofthe BRCAI 185delAG mutation is
approximately 1 percent in Ashkenazi Jewish individuals. Nature Genet 11:
198-200
Syvanen AC, Aalto-Setala K, Kontula K and Soderlund H (1989) Direct sequencing
ofaffinity-captured amplified human DNA: application to the detection of
apolipoprotein Epolymorphism. FEBS Lett 258: 71-74
Szabo CI and King MC (1995) Inherited breast and ovarian cancer. Hum Mol Genet
4:1811-1817
Wooster R, Bignell G, Lancaster J, Swift S, Seal S, Mangione J, Collins N, Gregory
S, Gumbs C, Micklem G, Barfoot R, Hamoudi R, Patel S, Rice C, Biggs P,
Hashim Y, Smith A, Connor F, Arason A, Gudmundsson J, Fucenec D, Kelsell
D, Ford D, Tonin P, Bishop DT, Surr NK, Ponder BAJ, Eeles R, Peto J, Deville
P, Comeliss C, Lynch H, Narod S, Lenoir G, Egilsson V, Barkadottir RB,
Easton DF, Bentley DR, Futreal PA, Ashworth A and Stratton MR (1995)
Identification ofthe breast cancer susceptibility gene BRCA2. Nature 378:
789-792
C CancerResearch Campaign 1998 British Journal ofCancer(1998) 77(11), 1880-1883